Newly FDA-Cleared Stereotactic System Can be Utilized with Pre-Op MRI or CT
Utilized for neurological procedures including biopsies, catheter placement and electrode introduction, the SmartFrame OR Stereotactic System can be combined with preoperative MRI or CT to ensure optimal placement of devices and instruments.
The Food and Drug Adminstration (FDA) has granted 510(k) clearance for the SmartFrame OR Stereotactic System, which reportedly facilitates optimal preoperative placement of instruments and devices for neurological procedures.
Comprised of the SmartFrame OR and the ClearPointer™ Optical Navigation Wand, the SmartFrame OR Stereotactic System can enhance preoperative planning for electrode introduction, catheter placement and brain biopsy procedures, according to ClearPoint Neuro, the manufacturer of the system. The company noted the SmartFrame OR can be combined with preoperative magnetic resonance imaging (MRI) or computed tomography (CT).
Utilized in combination with the SmartFrame OR and a compatible stereotactic optical navigation system, the ClearPointer Optical Navigation Wand facilitates patient registration and navigation, according to ClearPoint Neuro.
“SmartFrame OR embodies over a decade of accumulated expertise in MRI-guided navigation, now enhanced with the latest OR imaging technology,” said Rob Rubio, a segment leader for neuromodulation at ClearPoint Neuro. “It offers surgeons flexible workflows, including iCT forward projection, enabling precise image-based corrections to achieve sub-millimetric accuracy.”
New MRI Research Explores Links Between Waist-to-Hip Ratio and Memory in Aging
March 13th 2025Researchers found that a higher waist-to-hip ratio in midlife was associated with higher mean diffusivity in 26 percent of total white matter tracts in the cingulum as well as the superior and inferior longitudinal fasciculus.
New Analysis Forecasts Substantial Cost Savings with the Use of Photon Counting CT for CCTA
March 8th 2025The use of ultra-high-resolution photon-counting CT in the evaluation of stable chest pain may significantly reduce follow-up tests and invasive coronary angiography (ICA) procedures, possibly resulting in millions in health-care cost savings, according to a cost-effectiveness analysis presented recently at the European Congress of Radiology.
